利索-全球专利检索

  1. 登录
  2. 注册

搜索结果

90 条记录 (耗时 0.032 秒)

    ACID PUMP ANTAGONIST FOR TREATMENT OF DISEASES ASSOCIATED WITH ABNORMAL GASTROINTESTINAL MOVEMENT
    63.
    发明公开
    ACID PUMP ANTAGONIST FOR TREATMENT OF DISEASES ASSOCIATED WITH ABNORMAL GASTROINTESTINAL MOVEMENT 有权
    ÄANT ANT ON IST EN EN EN EN EN EN EN EN EN EN EN EN EN EN EN EN EN EN EN EN EN EN EN EN EN EN EN EN EN EN EN EN

    公开(公告)号：EP2452680A1

    公开(公告)日：2012-05-16

    申请号：EP10797193.9

    申请日：2010-07-09

    申请人： RaQualia Pharma Inc

    发明人： TAKAHASHI, Nobuyuki ,  KOIZUMI, Shinichi

    IPC分类号： A61K31/4188 ,  A61K31/4184 ,  A61K31/437 ,  A61K31/506 ,  A61K45/00 ,  A61P1/00 ,  A61P1/04 ,  A61P1/14 ,  A61P11/06 ,  A61P31/04 ,  A61P43/00

    摘要： The present invention relates to a use of a compound having an acid pump antagonistic activity, a pharmaceutically acceptable salt thereof or a pharmaceutical composition thereof for the manufacture of a medicament for prevention or treatment of diseases in which abnormal gastrointestinal motility is involved. In addition, the present invention relates to the method of prevention or treatment including administering to a human or animal. The compound, the pharmaceutically acceptable salt thereof, or pharmaceutical compositions containing them, may be used in combination with one or more second active agent. Further, the present invention relates to pharmaceutical compositions and kits comprising a compound having an acid pump antagonistic activity or a pharmaceutically acceptable salt thereof for the prevention or treatment of said diseases.

    摘要翻译： 本发明涉及具有酸泵拮抗活性的化合物，其药学上可接受的盐或其药物组合物在制备用于预防或治疗其中涉及异常胃肠蠕动的疾病的药物中的用途。 此外，本发明涉及预防或治疗方法，包括对人或动物施用。 化合物，其药学上可接受的盐或含有它们的药物组合物可以与一种或多种第二活性剂组合使用。 此外，本发明涉及药物组合物和试剂盒，其包含具有酸泵拮抗活性的化合物或其药学上可接受的盐，用于预防或治疗所述疾病。

    SELECTIVE EP4 RECEPTOR AGONISTIC SUBSTANCE FOR TREATMENT OF CANCER
    65.
    发明公开
    SELECTIVE EP4 RECEPTOR AGONISTIC SUBSTANCE FOR TREATMENT OF CANCER 有权
    SELEKTIVE EP4-REZEPTORANTAGONISTENSUBSTANZ ZUR KREBSBEHANDLUNG

    公开(公告)号：EP2422779A1

    公开(公告)日：2012-02-29

    申请号：EP10767106.7

    申请日：2010-04-22

    申请人： RaQualia Pharma Inc

    发明人： TAKE, Yukinori ,  KOIZUMI, Shinichi ,  OKUMURA, Takako ,  NONOMURA, Kazuhiko

    IPC分类号： A61K31/192 ,  A61K31/437 ,  A61K31/4412 ,  A61P35/00 ,  A61P43/00 ,  C07D213/64 ,  C07D471/04

    CPC分类号： C07D471/04 ,  A61K31/192 ,  A61K31/437 ,  A61K31/44 ,  A61K31/4412 ,  A61K45/06 ,  C07C235/60 ,  C07D213/82

    摘要： This invention provides a medicament for the treatment of cancer, which cause a reduction of cancer. This invention relates to use of a compound which has inhibitory activities against prostaglandin E2 receptor (EP4 receptor) and is represented by the following general formula (I), (II), (III), or (IV), or a pharmaceutically acceptable salt thereof, or a pharmaceutical composition comprising the compound or the salt for the manufacture of a medicament for the treatment of cancer. The invention relates to a method for treatment of cancer comprising administering the compound or a pharmaceutically acceptable salt thereof, or a pharmaceutical composition comprising the compound or the salt to humans or animals. The compound or a pharmaceutically acceptable salt thereof, or the pharmaceutical composition may be used in combination with one or more second active agents.

    摘要翻译： 本发明提供了一种用于治疗导致癌症减少的癌症的药物。 本发明涉及对前列腺素E2受体（EP4受体）具有抑制活性的化合物的用途，由以下通式（I），（II），（III）或（IV）表示，或其药学上可接受的盐 或包含该化合物或盐的药物组合物，用于制备用于治疗癌症的药物。 本发明涉及一种治疗癌症的方法，其包括将化合物或其药学上可接受的盐或包含该化合物或盐的药物组合物给予人或动物。 化合物或其药学上可接受的盐或药物组合物可以与一种或多种第二活性剂组合使用。

    BENZIMIDAZOLE DERIVATIVES AS SELECTIVE ACID PUMP INHIBITORS
    67.
    发明公开
    BENZIMIDAZOLE DERIVATIVES AS SELECTIVE ACID PUMP INHIBITORS 有权
    苯并咪唑选择性酸泵抑制剂

    公开(公告)号：EP2081939A1

    公开(公告)日：2009-07-29

    申请号：EP07825160.0

    申请日：2007-09-17

    申请人： RaQualia Pharma Inc

    发明人： KOIKE, Hiroki ,  MORITA, Mikio

    IPC分类号： C07D491/04 ,  A61K31/4188 ,  A61P1/04 ,  A61P1/08 ,  A61P11/06

    CPC分类号： C07D491/052 ,  C07D491/14

    摘要： Abstract This invention relates to compounds of the formula (I): or a pharmaceutically acceptable salt thereof, wherein: R1, R2, R3, R4, A and E are each as described herein or a pharmaceutically acceptable salt, and compositions containing such compounds and the method of treatment and the use, comprising such compounds for the treatment of a condition mediated by acid pump antagonistic activity such as, but not limited to, as gastrointestinal disease, gastroesophageal disease, gastroesophageal reflux disease (GERD), laryngopharyngeal reflux disease, peptic ulcer, gastric ulcer, duodenal ulcer, NSAID-induced ulcers, gastritis, infection of Helicobacter pylori, dyspepsia, functional dyspepsia, Zolliπger-Ellison syndrome, non-erosive reflux disease (NERD), visceral pain, cancer, heartburn, nausea, esophagitis, dysphagia, hypersalivation, airway disorders or asthma.